The Amyris stock drop can be explained by the fact that the company was unable to timely file its annual report for 2018 due to insufficient control over its financial activity. The annual report was delayed due to the financial implications of several deals made at the end of 2018.
Full Answer
Who owns Amyris stock?
Company insiders that own Amyris stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo, L John Doerr and Nicole Kelsey. View institutional ownership trends for Amyris.
What's happening with Amyris Inc's supply chain?
While the company faced supply chain troubles in the third quarter, it's taking steps to rectify the situation. Amyris is developing ingredient-production facilities in Brazil and Reno that are expected to begin operations in 2022.
Why did Amyris’s Q3 earnings miss estimates?
Amyris missed sales and earnings estimates. The company faces supply chain challenges. Failing to deliver on both the top and bottom lines, synthetic-biology specialist Amyris ( NASDAQ:AMRS) reported disappointing third-quarter 2021 earnings results yesterday after the market closed.
Is Amyris (Amyr) a good buy on Wall Street?
Amyris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $22.00, Amyris has a forecasted upside of 427.6% from its current price of $4.17.
Will Amyris stock go back up?
On average, Wall Street analysts predict that AMYRIS's share price could reach $20.10 by May 25, 2023. The average AMYRIS stock price prediction forecasts a potential upside of 652.81% from the current AMRS share price of $2.67.
Why did Amyris stock drop so much?
Failing to meet analysts' top-line estimates, Amyris reported a 30% year-over-year decline in its ingredients business, to the chagrin of investors, and it seems as if the company will continue to face challenges in the fourth quarter.
Is Amyris stock a good buy?
Amyris has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Why is Amrs going down?
Shares of industrial biotechnology company Amyris (AMRS 30.23%) plummeted as much as 30% today after it was accused in a lawsuit of patent infringement and trade secret misappropriation. Shares closed the session down 26%.
Is Amyris a good company?
Amyris is a fast paced, challenging, and fun company to work for. The research and development is cutting edge and products are scaled-up and moved into manufacturing with impressive speed. Overall, the employees are very collaborative and work well in teams.
What does Amyris Inc do?
Amyris, Inc. produces and distributes chemical products. The Company serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets. Amyris serves customers worldwide.
Does amyris pay dividends?
AMYRIS (NASDAQ: AMRS) does not pay a dividend.
Is Amrs a buy or sell?
Piper Sandler is very positive about AMRS and gave it a "" rating on May 25, 2022. The price target was changed from 2.12 to 2.75. Over the last 90 days, this security got 1 buy, 0 sell, and 0 hold ratings.
What is the long range forecast for AMRS stock?
The 7 analysts offering 12-month price forecasts for Amyris Inc have a median target of 9.00, with a high estimate of 22.00 and a low estimate of 2.50. The median estimate represents a +296.48% increase from the last price of 2.27.
Is Zymergen publicly traded?
The April 2021 Zymergen IPO raised $530 million, going public at more than 200 times 2020 revenue.
Is Amyris a buy right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 buy ratin...
How has Amyris' stock price been impacted by COVID-19 (Coronavirus)?
Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organizati...
When is Amyris' next earnings date?
Amyris is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for Amyris .
How were Amyris' earnings last quarter?
Amyris, Inc. (NASDAQ:AMRS) issued its earnings results on Tuesday, March, 1st. The biotechnology company reported ($0.43) EPS for the quarter, miss...
When did Amyris' stock split? How did Amyris' stock split work?
Shares of Amyris reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The nu...
What guidance has Amyris issued on next quarter's earnings?
Amyris issued an update on its FY 2021 earnings guidance on Monday, February, 7th. The company provided earnings per share guidance of for the peri...
What price target have analysts set for AMRS?
4 brokerages have issued 1 year price objectives for Amyris' stock. Their forecasts range from $15.00 to $30.00. On average, they expect Amyris' st...
Who are Amyris' key executives?
Amyris' management team includes the following people: John G. Melo , President, Chief Executive Officer & Director ( LinkedIn Profile ) Eduardo...
What is John Melo's approval rating as Amyris' CEO?
53 employees have rated Amyris CEO John Melo on Glassdoor.com . John Melo has an approval rating of 54% among Amyris' employees. This puts John Me...
NASDAQ: AMRS
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What happened
Failing to deliver on both the top and bottom lines, synthetic-biology specialist Amyris ( AMRS -3.63% ) reported disappointing third-quarter 2021 earnings results yesterday after the market closed.
So what
Although the company reported a year-over-year sales increase of 39.7%, it didn't seem to be enough to satisfy investors' appetites. Like Wall Street analysts, investors were expecting the company to report more on the top line.
Now what
While the company faced supply chain troubles in the third quarter, it's taking steps to rectify the situation. Amyris is developing ingredient-production facilities in Brazil and Reno that are expected to begin operations in 2022.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
AMRS latest development
On November 8, 2021, Amyris, Inc. (AMRS) released financial results for its third quarter ended September 30, 2021.
AMRS Convertible Senior Notes offer
On November 8, 2021, Amyris, Inc. (AMRS) proposed to offer a $400.0 million aggregate principal amount of convertible senior notes due 2026. The notes are to be offered and sold in a private placement to persons reasonably believed to be qualified institutional buyers.
AMRS partnership with ImmunityBio
On November 8, 2021, Amyris, Inc. (AMRS), entered into a 50:50 joint venture arrangement with ImmunityBio, Inc. (IBRX), to accelerate the commercialization of a leading next-generation COVID-19 vaccine.
AMRS collaboration with Inscripta
On October 5, 2021, Amyris, Inc. (AMRS) licensed the Onyx genome engineering platform from Inscripta. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality.
Conclusion
The recent financial results missed the revenue estimates and also it reported loss, due to which it went down in the after-hours on Monday. There are high chances that it will continue to decline on Tuesday as well.
Who bought Amyris stock?
AMRS stock was purchased by a variety of institutional investors in the last quarter, including Golden Green Inc., and Traynor Capital Management Inc.. Company insiders that have bought Amyris stock in the last two years include Frank Kung, and L John Doerr.
When did Amyris stock split?
Amyris's stock reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.
When is Amyris earnings call?
How can I listen to Amyris' earnings call? Amyris will be holding an earnings conference call on Thursday, August 5th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
Who is the CEO of Amyris?
Amyris CEO on the company's Q1 earnings report. John Melo , Amyris CEO, joined Yahoo Finance Live to discuss the company's first-quarter earnings report and why the company is teaming up with Ingredion. Motley Fool • 3 months ago.
Who is Amyris Inc?
Amyris, Inc. (AMRS), a leader in the development of sustainable ingredients through synthetic biotechnology , announced the acquisition of OLIKA Inc., a clean wellness company. The terms of the deal were not disclosed.
Amyris Stock History
The company released its IPO on NASDAQ in October 2010. During the past year, it has made investors worry many times because of Amyris stock drop. Its shares went up in August 2018, when the company reported significant royalty payouts on the Vitamin E partnership.
Why Is Amyris Stock Falling?
At the beginning of the year, several investors filed a lawsuit against the company for having violated legislation pertaining to securities and trading regulations on US stock exchanges.
Amyris Stock Price
Their stock price is currently at $3.02. Over the past year, AMRS stock price has dropped and is down by -53.39%. Therefore, it can be said that the cost of these shares indicate a steady downward trend.
Amyris Stock Drop Forecast
Actually, Amiris, Inc. actively searches for new business development opportunities. Perhaps cosmetic supplies based on cultivated cannabinoids will become the products that investors have been waiting for such a long time. The company can refocus on cannabinoid ingredients derived from genetically engineered microbes.
What happened
Shares of Amyris ( AMRS 4.30% ) fell more than 22% today after the business filed a form NT 10-K with the Securities and Exchange Commission. That's the ominous filing code for the "notification of inability to timely file form 10-K," which is the annual report for a business.
So what
Wall Street appears to have been caught off guard by the recent admissions, but the NT 10-K filing didn't actually contain any new information.
Now what
As is the case for many synthetic biology companies past and present, Amyris has relied much too heavily on storytelling and not enough on building a sustainable business. Most of the products at the heart of that storytelling haven't been successfully commercialized.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
